Meta briefly limited free use of its Ray-Ban glasses’ hearing feature to three hours a month, then paused the plan on July 25, 2026. The episode exposes what actually separates smart glasses as hearing aids from the real thing — and it is not the microphones.
What is the depression nasal spray? A concise, evidence-based look at esketamine (Spravato) — its mechanism, FDA-approved uses, trial results, and commercial rise.
A 2026 study pitted four AI models against 100 doctors on AI ENT referral decisions. Diagnosis was a tie—so where did the models actually pull ahead?
A new one-hour brush swab promises to spot oral cancer fast — but what does its oral cancer swab test accuracy actually mean, and why does a positive result still send you for a biopsy?
OTC hearing aids went from cheap amplifiers to AI devices that rival prescription aids in just three years. An otolaryngologist explains how good they really are now, where the limits are still clear, and when you still need a clinic.
The earbud feature everyone is discussing is live translation. The quieter capability beneath it — AI speech clarification, or making same-language speech intelligible for people who hear sound but miss words — matters more. The clinical evidence is encouraging and narrow: AI does not restore lost hearing, but it can make residual hearing more usable.
Can AI de-escalation in HPV throat cancer show which patients safely need less treatment? A 2026 NCDB study trained survival models to find out — with limits.
From depression to OCD to tinnitus — a clear-eyed look at what TMS therapy actually treats, where the science is strong, and where it falls short.
The AirPods hearing test makes screening effortless—but Apple’s 160,000-person study shows a “normal” result doesn’t always mean normal hearing. Here’s what an ENT says matters.
An AI-designed anti-TSLP antibody is in Phase 3 for asthma. Whether it can extend to nasal polyps (CRSwNP) depends on more than a shared mechanism.
